Intervention Protocol

You have free access to this content

Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)

  1. Toni Redman1,
  2. Elly Scheermeyer2,
  3. Makoto Ogawa2,
  4. Eddie C Sparks2,
  5. Jeremy C Taylor2,
  6. Vi T Tran2,
  7. Nancy Sturman3,
  8. Mieke L van Driel2,4,5,*

Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group

Published Online: 13 AUG 2014

DOI: 10.1002/14651858.CD011144


How to Cite

Redman T, Scheermeyer E, Ogawa M, Sparks EC, Taylor JC, Tran VT, Sturman N, van Driel ML. Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs) (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD011144. DOI: 10.1002/14651858.CD011144.

Author Information

  1. 1

    Child Development and Behaviour Service, Community Child Health, Gold Coast, Queensland, Australia

  2. 2

    The University of Queensland, School of Medicine, Brisbane, Queensland, Australia

  3. 3

    The University of Queensland, Discipline of General Practice, School of Medicine, Brisbane, Queensland, Australia

  4. 4

    Bond University, Centre for Research in Evidence-Based Practice (CREBP), Gold Coast, Queensland, Australia

  5. 5

    Ghent University, Department of General Practice and Primary Health Care, Ghent, Belgium

*Mieke L van Driel, m.vandriel@uq.edu.au. mieke.vandriel@ugent.be.

Publication History

  1. Publication Status: New
  2. Published Online: 13 AUG 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the efficacy and safety of methylphenidate for 1) features of ADHD such as hyperactivity, impulsivity, and concentration, and 2) the core features of ASD (social, communication, and behavioural problems) in children aged six to 18 years with ASD.